局部晚期宫颈癌患者按 disaggregated 亚裔美国人及夏威夷原住民/太平洋岛民分组接受指南一致性治疗:美国国家癌症数据库分析
研究基于美国国家癌症数据库2004—2020年48,116例II–IVA期宫颈癌患者,比较 disaggregated 亚裔美国人(AA)与夏威夷原住民/太平洋岛民(NH/PI)接受指南一致性治疗(同步放化疗、近距离放疗且8周内完成治疗)的比例。AA患者中仅82%东南亚裔接受同步化疗,低于南亚裔的91%(p=0.026);南亚裔中位总生存期158个月,长于东南亚裔的113个月(p<0.001)。结论认为不同种族和族裔亚组在接受标准治疗方面存在差异。
要点
- AA患者中东南亚裔仅82%接受同步化疗,低于南亚裔的91%(p=0.026)。
- 南亚裔中位总生存期158个月,长于东南亚裔的113个月(p<0.001)。
- NH/PI患者较AA患者更常在较年轻时诊断(53% vs 30%,p<0.001)。
核心结论
- 不同种族和族裔亚组在接受宫颈癌标准治疗方面存在差异。
- 作者认为必须对种族和族裔数据进行 disaggregation,以理解潜在的诊疗差异并制定干预措施以实现健康公平。
研究设计与样本
- 研究为基于美国国家癌症数据库的分析,纳入2004—2020年II–IVA期宫颈癌患者。
- 共纳入48,116例患者,其中AA 2107例(4%),NH/PI 171例(<1%)。
- AA患者进一步分为东亚裔、南亚裔和东南亚裔;NH/PI患者作为独立种族亚组。
- 主要结局为接受指南一致性治疗的比例,定义为放疗联合同步化疗、近距离放疗且8周内完成治疗。
主要发现
- AA患者中36%为东南亚裔,31%为东亚裔,12%为南亚裔,21%因数据缺失或未知无法进一步 disaggregation。
- NH/PI患者较AA患者更常在较年轻时诊断(53% vs 30%,p<0.001),合并症比例更高(18% vs 14%,p<0.001)。
- AA亚组中,东南亚裔仅82%接受同步化疗,低于南亚裔的91%(p=0.026)。
- AA亚组中,南亚裔中位总生存期最长(158个月),东南亚裔为113个月(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite the within-group heterogeneity, Asian American (AA) and Native Hawaiian and Pacific Islander (NH/PI) patients are often grouped together. We compared the patterns of guideline-concordant care for locally advanced cervical cancer for disaggregated AA and NH/PI patients. METHODS: Patients with stage II-IVA cervical cancer between 2004 and 2020 were identified from the National Cancer Database. AA patients were disaggregated as East Asian (EA), South Asian (SA), and Southeast Asian (SEA). NH/PI patients were classified as a distinct racial subgroup. The primary outcome was the proportion undergoing guideline-concordant care, defined by radiation therapy with concurrent chemotherapy, brachytherapy, and completion of treatment within eight weeks. RESULTS: Of 48,116 patients, 2107 (4%) were AA and 171 (<1%) were NH/PI. Of the AA patients, 36% were SEA, 31% were EA, 12% were SA, and 21% could not be further disaggregated due to missing or unknown data. NH/PI patients were more likely to be diagnosed at an early age (53% NH/PI vs. 30% AA, p < 0.001) and have higher rates of comorbidities (18% NH/PI vs. 14% AA, p < 0.001). Within the AA subgroups, only 82% of SEA patients received concurrent chemotherapy compared to 91% of SA patients (p = 0.026). SA patients had the longest median OS (158 months) within the AA subgroups compared to SEA patients (113 months, p < 0.001). CONCLUSION: Disparities exist in the receipt of standard of care treatment for cervical cancer by racial and ethnic subgroups. It is imperative to disaggregate race and ethnicity data to understand potential differences in care and tailor interventions to achieve health equity.
引用
- Lee SS, Gold HT, Kwon SC, et al. Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis. Gynecol Oncol. 2024. PMID: 38262236. doi:10.1016/j.ygyno.2023.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。